Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the non-injectable insulin market grown in recent years?

The non-injectable insulin market has expanded significantly in recent years and is expected to increase from $1.92 billion in 2024 to $2.16 billion in 2025 at a CAGR of 12.1%. Key factors driving past growth include enhanced patient compliance, addressing needle phobia, improved quality of life, easier administration, and better blood glucose control.

How is the non-injectable insulin market size expected to evolve during the forecast period?

The non-injectable insulin market is projected to experience rapid expansion in the coming years, reaching $3.17 billion in 2029 at a CAGR of 10.1%. Growth factors include a strong focus on patient compliance, ongoing solutions for needle phobia, enhanced quality of life, improved safety measures, and reduced infection and injury risks. Key trends include technological advancements, digital health integration, nanotechnology applications, and combination therapies.

Get your non-injectable insulin market report here!

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which key drivers are propelling the non-injectable insulin market’s growth?

The growing prevalence of obesity and diabetes is anticipated to drive the expansion of the non-injectable insulin market. Obesity results from an imbalance between calorie intake and expenditure, leading to excessive fat accumulation, while diabetes is a group of metabolic disorders characterized by prolonged high blood sugar levels. Non-injectable insulin plays a key role in managing both conditions by improving adherence, aiding weight management, and offering convenient treatment alternatives. For example, in 2022, the World Heart Federation reported that global obesity rates were rising, with 2.3 billion individuals—both children and adults—classified as overweight or obese in 2021, a number expected to reach 2.7 billion by 2025. Additionally, an April 2023 report from the British Diabetic Association indicated that 4.3 million people in the UK have diabetes, while over 2.4 million are at high risk of developing type 2 diabetes. The 2021-22 registration figures saw an increase of 148,951 from the previous year. Consequently, the increasing rates of obesity and diabetes are fueling the non-injectable insulin market’s growth.

What are the market segments in the non-injectable insulin industry?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Which leading companies are shaping the growth of the non-injectable insulin market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

What key trends are currently impacting the non-injectable insulin market’s development?

Major players in the non-injectable insulin market are concentrating their efforts on the innovation of drug delivery technologies, such as needle-free oral insulin sprays, in order to enhance the quality of life of individuals who need to manage their diabetes with multiple insulin injections. A needle-free insulin spray offers an uncomplicated and painless method for controlling blood sugar levels, as doses can be administered directly into the mouth. To illustrate, NiedlFree Technologies, an Indian technology firm, launched Ozulin, an oral insulin spray, in November 2023. Designed to be more user-friendly and beneficial for those who struggle with traditional injectable insulin procedures, this spray is particularly aimed at diabetics. Should it gain approval, Ozulin could revolutionise the experience of diabetes patients, providing a pain-free and more practical substitute for insulin injections.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

Which geographic areas are influencing the growth of the non-injectable insulin market?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Insulin Patch Pumps Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report

Iron Deficiency Injectable Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: